Prestige Brands Holdings, Inc. — FY2017 Form 10-K
Reporting period: Fiscal year ended March 31, 2017, with FY2016 comparison. The filing is not a standalone FY2016 Q4 report; it also reports the quarter ended March 31, 2017. The registrant filed under the name Prestige Brands Holdings, Inc.
Business context and financial results
The company markets OTC healthcare and household cleaning products through North American OTC Healthcare, International OTC Healthcare, and Household Cleaning segments. Fiscal 2017 included the January 2017 acquisition of C.B. Fleet Company for approximately $823.7 million and the sale of several non-core brands.
| Metric | FY2017 | FY2016 |
|---|---|---|
| Total revenue | $882.1 million | $806.2 million |
| Gross profit / margin | $500.3 million / 56.7% | $467.2 million / 57.9% |
| Operating income | $205.6 million | $260.3 million |
| Net income | $69.4 million | $99.9 million |
| Diluted EPS | $1.30 | $1.88 |
| Cash from operating activities | $147.8 million | $174.4 million |
For the March 2017 quarter, revenue was $240.7 million and net income was $11.1 million, compared with $207.9 million and $13.9 million, respectively, in the March 2016 quarter.
At March 31, 2017, cash was $41.9 million, current assets were $334.4 million and current liabilities were $162.0 million. Principal debt was $2.222 billion (net carrying debt of $2.194 billion), with $82.6 million of available ABL borrowing capacity. Capital expenditures were $3.0 million. The company reported $694.6 million of cash used in investing activities, chiefly reflecting the Fleet acquisition.
Material changes versus the prior comparable period
- Revenue rose 9.4%, mainly from acquired DenTek and Fleet sales; excluding acquisition contributions, management reported declines in North American OTC revenue, substantially affected by divestitures.
- Gross margin declined 1.2 percentage points, reflecting acquired-brand mix and Fleet purchase-accounting charges. Advertising and promotion expense rose to $128.4 million from $110.8 million.
- Operating income and net income fell, including a $51.8 million net pre-tax divestiture loss, higher acquisition/integration costs, and net interest expense of $93.3 million versus $85.2 million.
- Operating cash flow declined $26.6 million. Fleet-related term financing increased principal debt from $1.653 billion at FY2016 year-end to $2.222 billion.
Outlook, risks, contingencies and unusual items
- No specific numerical revenue or earnings guidance is provided. Management said operating cash flow and existing credit facilities should fund working capital and capital expenditures over the next 12 months, excluding acquisitions, while noting this is not assured.
- Management expected covenant compliance in FY2018; the company reported compliance at March 31, 2017. Debt agreements impose leverage, interest-coverage and fixed-charge tests and restrict certain transactions. A one-percentage-point increase in rates on variable-rate debt was estimated to reduce annual pre-tax earnings and cash flow by about $9.3 million.
- Key risks include substantial leverage, reliance on Walmart (21.1% of gross revenue and 33.1% of receivables), competition and private labels, dependence on third-party manufacturers, acquisition integration, regulation, and disruption at the single primary U.S. distribution center. The company also operates the acquired Fleet manufacturing facility.
- The annual impairment review found no impairment, but Beano and Comet trade names each had only 9% valuation headroom; management disclosed sensitivity to lower cash flows or higher discount rates. Painstop’s useful life was changed in response to Australia’s planned February 2018 restriction on OTC codeine sales.
- A Brazilian regulator required a recall of a specific product after the Fleet facility was found noncompliant with Brazilian standards for its manufacture. Management did not expect a material business impact but noted potential implications for other products or markets were uncertain. Routine litigation was not expected to have a material adverse effect, subject to the uncertainties described in the filing.
- The company recorded no goodwill or intangible-asset impairment. Management and the auditor reported effective internal control over financial reporting, but Fleet was excluded from the assessment because of the recent acquisition.
Important facts for investors to verify
- How much future revenue and margin growth is organic, versus attributable to Fleet and DenTek, and how integration is progressing.
- Debt repayment capacity, variable-rate exposure, covenant headroom and the effect of future acquisition spending.
- Whether Beano and Comet meet the assumptions supporting their limited impairment headroom, and the effect of codeine restrictions on Painstop.
- Walmart-related customer and receivables concentration, manufacturer supply continuity, and the scope or consequences of the Brazilian recall.
- The reported divestiture loss, acquisition purchase-price allocations and Fleet’s reported post-acquisition revenue of $38.7 million and net loss of $2.5 million.